

UBS Investment Research First Read: Bharat Heavy Elec.

Powering ahead

■ Margin growth and backlog growth beats estimates

In 2QFY08, sales grew 21%YoY to Rs44.4bn, EBITDA increased 52% to Rs6.95bn (margins improved 321bps vs. UBSe of 50bps increase), recurring PAT grew 30% to Rs4.68bn (UBSe: Rs4.5bn). Including IT related net write back of Rs2.2bn, reported PAT grew 91% to Rs6.9bn. The order backlog rose 16%QoQ to Rs726bn (UBSe of Rs680bn), as order inflows was Rs146bn during 2Q.

■ Margins expanded on lower raw material and staff costs

The raw material costs declined 192 bps (48.7% of sales in 2QFY08 vs 50.7% of sales in 2QFY07) and staff costs were lower by 126bps in 2QFY08 (14.2% of sales vs. 15.4% in 2QFY07). The power sector sales grew 22%YoY, and industrials by 20%. The PBIT margins of power division came in at 23.1% vs. 21.3% in 2QFY07, and industrials in 2QFY08 at 14.1% vs. 12.2% in 2QFY08.

■ On track for FY08E

1HFY08 recurring net profit is 20% of our full year FY08 estimates, respectively. Despite superior order inflows and margin expansion in 2QFY08, we are not changing our estimates as yet. The key share price driver over the next 6-12 months in addition to earnings momentum would be news flow on supercritical order wins from NTPC and from state boards.

■ Valuation: Under Review

In light of the stock's recent outperformance, we are placing our price target and rating under review. Our price target is based on DCF, with 20% mid-term (FY 10-15E) growth, WACC of 11.2%, and terminal growth of 6%. For BHEL, key risks are competition and execution.

Highlights (Rsm)	03/06	03/07	03/08E	03/09E	03/10E
Revenues	135,043.81	174,203.00	214,559.86	293,936.01	388,200.51
EBIT (UBS)	23,398.45	33,321.20	41,807.60	56,332.72	72,090.16
Net Income (UBS)	16,659.37	24,141.80	31,553.94	41,721.57	52,241.92
EPS (UBS, Rs)	34.03	49.32	64.46	85.23	106.72
Net DPS (UBS, Rs)	7.25	12.25	22.00	26.00	27.00
Profitability & Valuation	5-yr hist av.	03/07	03/08E	03/09E	03/10E
Profitability & Valuation EBIT margin %	5-yr hist av. 13.9	03/07 19.1	03/08E 19.5	03/09E 19.2	03/10E 18.6
EBIT margin %	13.9	19.1	19.5	19.2	18.6
EBIT margin % ROIC (EBIT) %	13.9 34.9	19.1 98.3	19.5 131.2	19.2 126.4	18.6 96.4
EBIT margin % ROIC (EBIT) % EV/EBITDA (core) x	13.9 34.9 7.5	19.1 98.3 13.9	19.5 131.2 25.1	19.2 126.4 18.5	18.6 96.4 14.5

Source: Company accounts, Thomson Financial, UBS estimates. (UBS) valuations are stated before goodwill, exceptionals and other special items. Valuations: based on an average share price that year, (E): based on a share price of Rs2,431.75 on 26 Oct 2007 23:39 HKT

Suhas Harinarayanan

Analyst Suhas.Hari@ubs.com +91-22-2286 2091 Pankaj Sharma

Associate Analyst pankaj-p.sharma@ubs.com +91-22-2286 2103

Global Equity Research

India

Industrial, Diversified

12-month rating (UR) Buy *

Unchanged

12m price target (UR) Rs2,475.00/US\$62.79 *Unchanged*

Price Rs2,431.75/US\$61.69
RIC: BHEL.BO BBG: BHEL IN

29 October 2007

Trading data (local/US\$)

52-wk range	Rs2,431.75	-977.88/US\$61.86-22.19
Market cap.		Rs1,190bn/US\$30.2bn
Shares o/s		490m (ORD)
Free float		32%
Avg. daily volume ('000)		204
Avg. daily valu	ıe (Rsm)	396.2

Balance sheet data 03/08E

Shareholders' equity	Rs107bn
P/BV (UBS)	11.1x
Net Cash (debt)	Rs73.7bn

Forecast returns

. or oddot rotarrio	
Forecast price appreciation	+1.8%
Forecast dividend yield	0.5%
Forecast stock return	+2.3%
Market return assumption	11.9%
Forecast excess return	-9.6%

EPS (UBS, Rs)

	03/08E		03/07
	UBS	Cons.	Actual
Q1E	-	-	4.83
Q2E	-	-	7.35
Q3E	-	-	13.64
Q4E	-	-	27.91
03/08E	64.46	64.46	
03/09E	85.23	<i>85.23</i>	

Performance (Rs)



Source: UBS www.ubs.com/investmentresearch

■ Bharat Heavy Electricals Limited

BHEL focuses on the Indian power equipment business, which accounted for 65% of revenue and 79% of PBIT for FY04. Its main customer is National Thermal Power Corporation (NTPC), accounting for over 50% of revenue. BHEL also services the power transmission, captive power plant, industrial equipment, and the transportation segments. Actual/deemed exports accounted for 24% of revenue in FY04, and the company has added several new markets to its portfolio. It is 68%-owned by the Government of India.

■ Statement of Risk

We believe the key risks fro BHEL are, 1) Execution related, 2) Increasing Competition and, 3) Earnings disappointment

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Required Disclosures

This report has been prepared by UBS Securities India Private Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

UBS Investment Research: Global Equity Rating Allocations

UBS 12-Month Rating	Rating Category	Coverage ¹	IB Services ²
Buy	Buy	55%	40%
Neutral	Hold/Neutral	36%	35%
Sell	Sell	9%	22%
UBS Short-Term Rating	Rating Category	Coverage ³	IB Services ⁴
Buy	Buy	0%	29%
Sell	Sell	0%	0%

^{1:}Percentage of companies under coverage globally within the 12-month rating category.

Source: UBS. Rating allocations are as of 30 September 2007.

UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition
Buy	FSR is > 6% above the MRA.
Neutral	FSR is between -6% and 6% of the MRA.
Sell	FSR is > 6% below the MRA.
UBS Short-Term Rating	Definition
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.

^{2:}Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

^{3:}Percentage of companies under coverage globally within the Short-Term rating category.

^{4:}Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

EXCEPTIONS AND SPECIAL CASES

US Closed-End Fund ratings and definitions are: Buy: Higher stability of principal and higher stability of dividends; Neutral: Potential loss of principal, stability of dividend; Reduce: High potential for loss of principal and dividend risk.

UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Reduce: Negative on factors such as structure, management, performance record, discount.

Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Companies Mentioned or Company Disclosure table in the relevant research piece.

Company Disclosures


Company Name	Reuters	12-mo rating	Short-term rating	Price	Price date
Bharat Heavy Electricals Limited	BHEL.BO	Buy (UR)	N/A	Rs2,431.75	26 Oct 2007

Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

Bharat Heavy Electricals Limited (Rs)



Source: UBS; as of 26 Oct 2007

Note: On August 4, 2007 UBS revised its rating system. (See 'UBS Investment Research: Global Equity Rating Definitions' table for details). From September 9, 2006 through August 3, 2007 the UBS ratings and their definitions were: Buy 1 = FSR is > 6% above the MRA, higher degree of predictability; Buy 2 = FSR is > 6% above the MRA, lower degree of predictability; Neutral 1 = FSR is between -6% and 6% of the MRA, higher degree of predictability; Neutral 2 = FSR is between -6% and 6% of the MRA, lower degree of predictability; Reduce 1 = FSR is > 6% below the MRA, higher degree of predictability; Reduce 2 = FSR is > 6% below the MRA, lower degree of predictability. The predictability level indicates an analyst's conviction in the FSR. A predictability level of '1' means that the analyst's estimate of FSR is in the middle of a narrower, or smaller, range of possibilities. A predictability level of '2' means that the analyst's estimate of FSR is in the middle of a broader, or larger, range of possibilities. From October 13, 2003 through September 8, 2006 the percentage band criteria used in the rating system was 10%.

Global Disclaimer

This report has been prepared by UBS Securities India Private Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries, UBS AG is referred to as UBS SA

This report is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute a representation that any investment strategy is suitable or appropriate to a recipient's individual circumstances or otherwise constitute a personal recommendation. It is published solely for informational purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities of developments referred to in the report. UBS does not undertake that involvers will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Research Wall initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthe

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are market counterparties or intermediate customers (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, private customers. UBS Limited is authorised and regulated by the Financial Services Authority. France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this report, the report is also deemed to have been prepared by UBS Securities France S.A. Germany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzedienstleistungsaufsicht (BaFin), Spain: Prepared by UBS Limited and UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). Turkey: Prepared by UBS Menkul Degerler AS on behalf of and distributed by UBS Limited and UBS Securities España SV, SA, UBS Securities España SV, SA, UBS Securities España SV, SA UBS Securities España SV, SA, UBS Securities Sespaña SV, SA, UBS Securit

The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. © UBS 2007. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

